Several funds that lost large amounts last year rebounded nicely in the first month of 2023.
Stephen TaubFebruary 21, 2023
Toru Hanai/Bloomberg
Finally some good news for investors in Casdin Capital. The firm’s biopharma hedge fund posted a 20 percent gain in January, an encouraging start to the year in what was a mixed month for the strategy
To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.